Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study

NCT01022086 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT01022086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01022086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study
Lead sponsor
Unity Health Toronto
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2009
Completion date
December 31, 2019
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage i-iv breast cancer (neo-adjuvant, adjuvant, locally advanced and metastatic)